Related Experiment Video
Updated: Apr 5, 2026
12:41
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
6.1K
Predicting paclitaxel-induced neutropenia using the DMET platform
Annemieke J M Nieuweboer1, Marcel Smid1, Anne-Joy M de Graan1
1Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
Pharmacogenomics
|August 13, 2015
Summary
Genetic variations in drug-metabolizing enzymes and transporters show limited ability to predict paclitaxel-induced neutropenia. Current pharmacogenetic models are not yet valuable for clinical practice in managing this chemotherapy side effect.
Area of Science:
- Pharmacogenomics
- Oncology
- Drug Metabolism
Background:
- Paclitaxel is a crucial chemotherapy agent.
- Paclitaxel-induced neutropenia significantly limits its clinical use.
- Predicting and managing neutropenia is essential for effective cancer treatment.
Purpose of the Study:
- To investigate the predictive ability of genetic variations in drug-metabolizing enzymes and transporters for paclitaxel-induced neutropenia.
- To develop and validate a pharmacogenetic model for predicting hematological toxicity.
Main Methods:
- A discovery and validation approach was employed.
- A DNA chip containing 1936 single nucleotide polymorphisms (SNPs) in 225 genes related to drug-metabolizing enzymes and transporters was utilized.
- The study included 279 patients treated with paclitaxel.
Main Results:
- A 10-SNP model achieved 43% sensitivity in the validation cohort.
- In patients treated every three weeks, sensitivity improved to 79% with 33% specificity.
- Statistical significance was not reached for any of the developed models.
Conclusions:
- Pharmacogenetic models based on drug-metabolizing enzymes and transporters currently have limited clinical utility for predicting paclitaxel-induced neutropenia.
- Further research is needed to develop more accurate predictive models for chemotherapy-induced toxicity.
